Citarinostat
|
- ₹0
- Product name: Citarinostat
- CAS: 1316215-12-9
- MF: C24H26ClN5O3
- MW: 467.95
- EINECS:
- MDL Number:MFCD28023593
- Synonyms:2-[(2-Chlorophenyl)phenylamino]-N-[7-(hydroxyamino)-7-oxoheptyl]-5-pyrimidinecarboxamide;Citarinostat;Citarinostat (ACY-241);ACY-241(CITARINOSTAT);2-((2-Chlorophenyl)(phenyl)aMino)-N-(7-(hydroxyaMino)-7-oxoheptyl)pyriMidine-5-carboxaMide;5-Pyrimidinecarboxamide, 2-[(2-chlorophenyl)phenylamino]-N-[7-(hydroxyamino)-7-oxoheptyl]-;HDAC-IN-2;Citarinostat(ACY-241,HDAC-IN-2)
| Manufacturer | Product number | Product description | Packaging | Price | Updated | Buy |
|---|
Properties
Density :1.293±0.06 g/cm3(Predicted)
storage temp. :Store at -20°C
solubility :≥23.4 mg/mL in DMSO; insoluble in H2O; ≥4.87 mg/mL in EtOH with ultrasonic
form :solid
pka :9.47±0.20(Predicted)
color :White to off-white
storage temp. :Store at -20°C
solubility :≥23.4 mg/mL in DMSO; insoluble in H2O; ≥4.87 mg/mL in EtOH with ultrasonic
form :solid
pka :9.47±0.20(Predicted)
color :White to off-white
Safety Information
| Symbol(GHS): |
|
|||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Signal word: | Warning | |||||||||||||||||||||||||||||||||||
| Hazard statements: |
|
|||||||||||||||||||||||||||||||||||
| Precautionary statements: |
|
Description
ACY-241 is an inhibitor of histone deacetylase 6 (HDAC6; IC50 = 2.6 nM). It is selective for HDAC6 over HDAC1-3, HDAC7, and HDAC9 (IC50s = 35, 45, 46, 7,300, and 137 nM, respectively), as well as HDAC4, HDAC5, and HDAC9 (IC50 = >20,000 nM for all). It reduces proliferation of A2780, TOV-21G, and MDA-MB-231 cells when used at a concentration of 3 μM and completely inhibits it and induces apoptosis at a concentration of 10 μM. ACY-241, when used in combination with paclitaxel , inhibits proliferation in MiaPaCa-2, TOV-21G, and T47D cells. It also reduces tumor growth in a MiaPaCa-2 mouse xenograft model when administered at a dose of 50 mg/kg in combination with paclitaxel. ACY-241, in combination with the somatostatin receptor agonist pasireotide , reduces hepatorenal cystogenesis in a rat model of polycystic liver disease.More related product prices
4-iodo-3-nitrobenzamide GDC-0879 HTH-01-015 AZ191 LJI308 CEP-18770 IMR-1 GDC-0623 CPI-455 CetilistatRelated product price
- 4-iodo-3-nitrobenzamide
₹12394.63 - GDC-0879
₹13314.75-53616.23 - HTH-01-015
₹13342.2-53712.9
